PCSK9 Inhibitors
High-yield Verified · Oct 2026Prototype: evolocumab
PCSK9 Inhibitors are injectable monoclonal antibodies used to lower LDL cholesterol and to reduce the risk of major cardiovascular events in adults at increased risk.
Medical view → mechanisms, drug comparisons and Step 1 pharmacology
Monoclonal antibodies against PCSK9 — the protein that sends LDL receptors to be destroyed. Self-injected under the skin; refrigerated; hypersensitivity is the main warning.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Keeping the liver’s LDL receptors in service
LDL cholesterol is cleared from the blood when it binds LDL receptors on liver cells and other tissues; the receptor–LDL complex is taken into the cell, and the receptors normally recycle back to the surface to clear more LDL. PCSK9, a protein made by liver cells and secreted into the plasma, binds LDL receptors and sends them to be degraded instead, so fewer receptors return and less LDL is cleared.
Evolocumab and alirocumab are monoclonal antibodies that bind PCSK9 and stop it binding the LDL receptor. More receptors stay available to clear LDL from the blood, so LDL cholesterol falls — typically by 50–60%, alone or with a statin, for as long as treatment continues. Statins themselves increase PCSK9 activity, which blunts their effect.
02 A self-injected antibody, not a pill
Both drugs are human monoclonal antibodies given by subcutaneous injection every 2 to 4 weeks, using prefilled pens, autoinjectors or syringes that patients or caregivers are trained to use. They are kept refrigerated and must not be frozen or shaken, and as monoclonal antibodies they are not known to be eliminated by the kidneys.
The names carry their own label: in the WHO naming scheme, -mab marks a monoclonal antibody, the -ci- infix a cardiovascular target and -u- a human antibody (evolo-c-u-mab, aliro-c-u-mab). Their main warning is hypersensitivity: angioedema has occurred with both, and hypersensitivity vasculitis with alirocumab.
Drug names
Indications
- Prevention of major cardiovascular events (such as myocardial infarction, stroke and unstable angina requiring hospitalization) in adults at increased risk
- Hypercholesterolemia — with diet and exercise to lower LDL-C, including heterozygous familial hypercholesterolemia (evolocumab from age 10, alirocumab from age 8) and homozygous familial hypercholesterolemia (evolocumab in adults and children 10 and older; alirocumab in adults)
Mechanism of action
Evolocumab and alirocumab are human monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds LDL receptors on hepatocytes and promotes their degradation in the liver; by blocking PCSK9 binding to the LDL receptor, the antibodies increase the number of LDL receptors available to clear LDL, lowering LDL cholesterol.
Therapeutic effects — what you'll see working
Success is a lower LDL cholesterol — measurable as early as 4 weeks after starting — and, over the long term, fewer heart attacks and strokes.
- ↓ LDL cholesterol by about half
- With more LDL receptors in service, LDL cholesterol typically falls by 50–60%, whether used alone or with a statin; the effect lasts as long as treatment continues.
- Fewer cardiovascular events
- Both are labeled to reduce the risk of major adverse cardiovascular events in adults at increased risk, such as myocardial infarction, stroke and unstable angina requiring hospitalization.
Adverse effects
Generally well tolerated: injection-site reactions, nasopharyngitis and upper respiratory infections are the common effects. The warning to know is hypersensitivity, including angioedema.
Interactions
Contraindications
The only contraindication on either label is a previous serious hypersensitivity reaction to the drug.
When to hold
Assess before giving — these findings mean hold the dose and act.
Labs & levels
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are PCSK9 Inhibitors used for?
How do PCSK9 Inhibitors work?
What are the serious side effects of PCSK9 Inhibitors?
When should a nurse hold PCSK9 Inhibitors, and what safety checks apply?
What labs should be monitored with PCSK9 Inhibitors?
See also
Slow heart rate & lower BP by blocking β-adrenergic receptors. Watch for bradycardia.
Lower BP by blocking angiotensin conversion. Classic dry cough & angioedema risk.
Lower LDL cholesterol via HMG-CoA reductase inhibition. Monitor for myopathy.
PPAR-α agonists that mainly lower triglycerides — used with diet for severe hypertriglyceridemia — with muscle, gallbladder, liver and kidney risks, highest for gemfibrozil combined with a statin.
Non-absorbed resins that trap bile acids in the gut, forcing the liver to use cholesterol and pull LDL from the blood. Constipation, drug binding and rising triglycerides are the issues to manage.
Six non-statin drugs with six targets: ezetimibe (intestinal cholesterol absorption), bempedoic acid (liver cholesterol synthesis), inclisiran (PCSK9 mRNA), niacin and icosapent ethyl (triglyceride-rich lipoproteins) and lomitapide (MTP, for homozygous FH only).
Sources
- REPATHA (evolocumab) — FDA label: indications, administration, storage, hypersensitivity, latex — FDA / DailyMed
- PRALUENT (alirocumab) — FDA label: indications, administration, storage, hypersensitivity — FDA / DailyMed
- PCSK9 Inhibitors — LDL-receptor recycling, PCSK9 and statins, LDL-C reduction — StatPearls (NCBI)
- The use of stems in the selection of INN (2018) — -mab, -ci- (cardiovascular), -u- (human) — World Health Organization
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.